WPD Pharmaceuticals
Holding Companies & Conglomerates · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
750 W Pender St Ste 401, Vancouver, Brit...Phone Number
+48 515262381Website
www.wpdpharmaceuticals.comRevenue
$84 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About WPD Pharmaceuticals
WPD Pharmaceuticals Inc. is focused on developing biological and chemical molecules for targeted therapy in brain glioma and other central nervous system cancers. The company currently has no active business operations and its primary asset consists of shares in its former subsidiary, WPD Pharmaceuticals Sp. zo.o., which specializes in oncology research and development. Following a restructuring, WPD lost control of the Polish subsidiary, which now represents approximately 7% of its total issued shares. The intended clients include stakeholders in the biotechnology and pharmaceutical sectors, particularly those involved in oncology.Explore more
WPD Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is WPD Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at WPD Pharmaceuticals
WPD Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when WPD Pharmaceuticals launches new products
Check if WPD Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if WPD Pharmaceuticals had a recent Job posting/layoffs
Check out if WPD Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once WPD Pharmaceuticals has new funding data
Earning: See what the market has to say on WPD Pharmaceuticals recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined WPD Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to WPD Pharmaceuticals
Compare insights from companies similar to WPD Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
WPD Pharmaceuticals is experiencing very low activity levels compared to other companies in the Holding Companies & Conglomerates sector.
What does this means?
WPD Pharmaceuticals is drawing exceptional interest within the Holding Companies & Conglomerates industry, suggesting notable developments or strong market momentum, learn more about WPD Pharmaceuticals.
WPD Pharmaceuticals Tech Stack
A closer look at the technologies used by WPD Pharmaceuticals
See more technologies
WPD Pharmaceuticals News & Media
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences
VANCOUVER, British Columbia, May 16, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has signed Annex No. 2 into its License Agreement with Wake Forest University Health Sciences (“WFUHS”). On April 22, 2022 WPD Pharmaceuticals Sp. z o.o. (“WPD Poland”), the Polish subsidiary of the Company, signed Annex No 2. into the License Agreement. Previous to Annex No. 2,WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project
Expert research team aiming to optimize the effects of radiotherapy of brain tumors Expert research team aiming to optimize the effects of radiotherapy of brain tumorsWPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1) announces that the Company’s board of directors (the “Board”) has approved a plan to restructure (the “Restructuring”) the outstanding capitalization of the Company’s wholly owned Polish subsidiary WPD Pharmaceuticals sp. z.o.o. (“WPD Poland”). Due to the occurrence of negative shareholders’ equity in WPD Poland, under Polish corporate law, WPD Poland is obligaWPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity
Commercially Reasonable Development Expenditures of at least US$2,000,000 going towards the development, testing, regulatory approval or commercialization of the licensed product, Berubicin, during the applicable development period Commercially Reasonable Development Expenditures of at least US$2,000,000 going towards the development, testing, regulatory approval or commercialization of the licensed product, Berubicin, during the applicable development period
Read more news
Top Holding Companies & Conglomerates Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding WPD Pharmaceuticals
Sign Up For FreeTo access detailed company insights
WPD Pharmaceuticals Inc. is focused on developing biological and chemical molecules for targeted therapy in brain glioma and other central nervous system cancers. The company currently has no active business operations and its primary asset consists of shares in its former subsidiary, WPD Pharmaceuticals Sp. zo.o., which specializes in oncology res... Read More
